RT @OncBrothers
#OncTwitter #MedTwitter #LCSM #bcsm #gism #gusm

How are you rationing Carbo?
- Any creative regimens for #BreastCancer (#TNBC or #HER2 pts in neoadj settings)?
- For Cis ineligible small cell #LungCancer? PDL-1 negative mNSCLC?
- Head & Neck Pts?
- How are you sharing this… https://twitter.com/i/web/status/1653848101679931393

So excited for #ESMOBreast23 this year. Who is joining me? 🇩🇪

Abstract submission deadline is February 21st!

@myESMO@twitter.com @OncoAlert@twitter.com #bcsm

RT @myESMO@twitter.com

#ESMOBreast23: Don’t miss the chance to present your data live in a collaborative environment looking into the latest science and education in #breastcancer (Berlin, Germany). Deadline 21 February.
🔗 http://ow.ly/7gWy50MvPVK

#bcsm #earlybreastcancer #advancedbreastcancer #TNBC

🐦🔗: https://twitter.com/myESMO/status/1617124916821630980

RT @TheGumFairy@twitter.com

#cancer update. The wee blighter has diminished significantly and surgery is booked for Feb 15th. Thank you to every single person that has supported me through this time. You’re all bloody wonderful ❤️❤️❤️ #cancerjourney #chemo #TNBC

🐦🔗: https://twitter.com/TheGumFairy/status/1611752502520692737

@derridalicious I am #TNBC too. Diagnosed at 45, in 2019. Stage 1, node negative. Grade 3. Found it early. Still did AC-T and rads. #triplenegativebreastcancer #breastcancer

Hey mastodon peeps. I am a #biomedical #scientist studying #Metastatic #cancer, specializing in #breastcancer (mainly #TNBC and #ILC. Professor at UMC Utrecht. Chairing the @elbcc and #COST action #lobsterpot. Working towards better diagnosis and prognosis for invasive cancer. Fed up with Twitter and the rubbish it spreads.

RT @JohnEbbenMDPhD
@TumorBoardTues @jane_meisel @quirogad @MPishvaian @BreastCaupdates @BreastCancerNow @TNBCFoundation @ArielleMedford @drteplinsky @EricaMarieRomn1 @jacobadashek @stolaney1 @MarkRobsonMD 4/5 #TumorBoardTuesday
Take🏠messages:
In HER2- mBC:
✅ Germline genetics 🔑: ~5% of BC= BRCAm; ⬆️% in #TNBC
✅ gBRCAm= PARPi preferred
✅ After PARPi, consider ADCs
✅ If PD-L1+ & gBRCAm negative, consider chemoIO

📚@jane_meisel @quirogad’s discussion:
https://threadreaderapp.com/thread/1605368723166355456.html

RT @JohnEbbenMDPhD
@TumorBoardTues @jane_meisel @quirogad @MPishvaian @BreastCaupdates @BreastCancerNow @TNBCFoundation @ArielleMedford @drteplinsky @EricaMarieRomn1 @jacobadashek @stolaney1 @MarkRobsonMD 4/5 #TumorBoardTuesday
Take🏠messages:
In HER2- mBC:
✅ Germline genetics 🔑: ~5% of BC= BRCAm; ⬆️% in #TNBC
✅ gBRCAm= PARPi preferred
✅ After PARPi, consider ADCs
✅ If PD-L1+ & gBRCAm negative, consider chemoIO

📚@jane_meisel @quirogad’s discussion:
https://threadreaderapp.com/thread/1605368723166355456.html

RT @JohnEbbenMDPhD
@TumorBoardTues @jane_meisel @quirogad @MPishvaian @BreastCaupdates @BreastCancerNow @TNBCFoundation @ArielleMedford @drteplinsky @EricaMarieRomn1 @jacobadashek @stolaney1 @MarkRobsonMD 4/5 #TumorBoardTuesday
Take🏠messages:
In HER2- mBC:
✅ Germline genetics 🔑: ~5% of BC= BRCAm; ⬆️% in #TNBC
✅ gBRCAm= PARPi preferred
✅ After PARPi, consider ADCs
✅ If PD-L1+ & gBRCAm negative, consider chemoIO

📚@jane_meisel @quirogad’s discussion:
https://threadreaderapp.com/thread/1605368723166355456.html

RT @JohnEbbenMDPhD
@TumorBoardTues @jane_meisel @quirogad @MPishvaian @BreastCaupdates @BreastCancerNow @TNBCFoundation @ArielleMedford @drteplinsky @EricaMarieRomn1 @jacobadashek @stolaney1 @MarkRobsonMD 4/5 #TumorBoardTuesday
Take🏠messages:
In HER2- mBC:
✅ Germline genetics 🔑: ~5% of BC= BRCAm; ⬆️% in #TNBC
✅ gBRCAm= PARPi preferred
✅ After PARPi, consider ADCs
✅ If PD-L1+ & gBRCAm negative, consider chemoIO

📚@jane_meisel @quirogad’s discussion:
https://threadreaderapp.com/thread/1605368723166355456.html

RT @jane_meisel
@shafiarahman_ @JohnEbbenMDPhD @TumorBoardTues @MPishvaian @quirogad @JasmineSukumar @DrGattiMays Some are using ctDNA used to track tx response in #TNBC and other breast cancers. Tumor markers (CA 27-29 or CA 15-3) can be used as well (in addition to scans and clinical status). ctDNA is more sensitive/specific than markers, arguably...

RT @myESMO@twitter.com

#ESMOBreast23: Sung-Bae Kim on this well-established event to submit and present your data LIVE, and get wide dissemination for your studies. Deadline 21 February 2023.
🔗 http://ow.ly/JBv050M9cR4

#bcsm #earlybreastcancer #advancedbreastcancer #TNBC #breastcancer

🐦🔗: https://twitter.com/myESMO/status/1605517898868465664

RT @jane_meisel
@shafiarahman_ @JohnEbbenMDPhD @TumorBoardTues @MPishvaian @quirogad @JasmineSukumar @DrGattiMays Some are using ctDNA used to track tx response in #TNBC and other breast cancers. Tumor markers (CA 27-29 or CA 15-3) can be used as well (in addition to scans and clinical status). ctDNA is more sensitive/specific than markers, arguably...

RT @valimpy: Triple Negative Breast Cancer: an alarming #BreastCancer.
🧑‍🔬#MSCA P70-IMMUNEBREAST is striving for unlocking lymphocyte-related responses modulated by a kinase (P70S6K), with high therapeutical potential for #TNBC and beyond.
👉https://cordis.europa.eu/project/id/893597
#HorizonEU
@mscactions

🐦🔗: https://n.respublicae.eu/REA_research/status/1603000614321004544

🇪🇺 initiatives, including #WomenTechEU CanceRusolution project, are developing new ways to treat Triple Negative Breast Cancer (#TNBC) for which there is no specific and efficient treatment in the market.

Learn more 👇
RT @HorizonMagEU: Triple negative breast cancer (#TNBC) is an aggressive, hard-to-treat form of #BreastCancer. EU researchers are looking for new ways to attack the tumour & stop it from spreading.

Read more ➡️ https://ec.europa.eu/research-and-innovation/en/horizon-magazine/breast-cancer-aggressive-variant-triggers-hunt-cures?pk_source=twitter&pk_medium=social&pk_content=health_science_in_society

#HorizonEU

🐦🔗: https://n.respublicae.eu/EU_EISMEA/status/1602607688386592769

RT @HorizonMagEU: Triple negative breast cancer (#TNBC) is an aggressive, hard-to-treat form of #BreastCancer. EU researchers are looking for new ways to attack the tumour & stop it from spreading.

Read more ➡️ https://ec.europa.eu/research-and-innovation/en/horizon-magazine/breast-cancer-aggressive-variant-triggers-hunt-cures?pk_source=twitter&pk_medium=social&pk_content=health_science_in_society

#HorizonEU

🐦🔗: https://n.respublicae.eu/EU_HaDEA/status/1601245694643539970

Relatively hopeful data from MARIO-3 (eganelisib, atezolizumab and nab-paclitaxel in 1L mTNBC. It has to be viewed cautiously as comparisons are made to historical population of IM130 but for now PI3K-gamma inhibition appears to be resurrected #TNBC #PI3Kgamma #EndCancer

https://www.businesswire.com/news/home/20221114005336/en/Infinity-Pharmaceuticals-Provides-MARIO-3-Update-in-Patients-with-Front-Line-Metastatic-Triple-Negative-Breast-Cancer-Suggesting-Potential-Long-Term-Patient-Benefit-of-Eganelisib

RT @Dr_RShatsky@twitter.com

I got into a screaming match with a jerk oncologist who sold out by working for insurance companies to deny claims today. My whole office stopped and stared. But then they clapped after they realized why I was yelling. @premera@twitter.com is denying my patient’s Keytruda for her #TNBC

🐦🔗: https://twitter.com/Dr_RShatsky/status/1593835608773865473

RT @Dr_RShatsky@twitter.com

I got into a screaming match with a jerk oncologist who sold out by working for insurance companies to deny claims today. My whole office stopped and stared. But then they clapped after they realized why I was yelling. @premera@twitter.com is denying my patient’s Keytruda for her #TNBC

🐦🔗: https://twitter.com/Dr_RShatsky/status/1593835608773865473

RT @Dr_RShatsky@twitter.com

I got into a screaming match with a jerk oncologist who sold out by working for insurance companies to deny claims today. My whole office stopped and stared. But then they clapped after they realized why I was yelling. @premera@twitter.com is denying my patient’s Keytruda for her #TNBC

🐦🔗: https://twitter.com/Dr_RShatsky/status/1593835608773865473

RT @Dr_RShatsky@twitter.com

I got into a screaming match with a jerk oncologist who sold out by working for insurance companies to deny claims today. My whole office stopped and stared. But then they clapped after they realized why I was yelling. @premera@twitter.com is denying my patient’s Keytruda for her #TNBC

🐦🔗: https://twitter.com/Dr_RShatsky/status/1593835608773865473